In patients with ventilator-associated pneumonia, systemic use of antibiotics is the cornerstone of medical management. Supplemental use of aerosolized antibiotics with intravenous antibiotics in both experimental and clinical studies has been shown to have the following pharmacologic benefits: (1) aerosolized antibiotics reach the infected lung parenchyma without crossing the pulmonary alveolar capillary barrier; (2) aerosolized antibiotics increase anti-bacterial efficacy through increased local antibiotic concentration; and (3) aerosolized antibiotics decrease systemic toxicity. These benefits may be particularly beneficial to treat pneumonia caused by multidrug-resistant pathogens. Clinical data on the benefits of aerosolized antibiotics are more limited. Studies to date have not clearly shown improvements in time to extubation, mortality, or other patient-centered outcomes. At present, amikacin, colistin, and ceftazidime are the most frequently used and studied aerosolized antibiotics. This review summarizes the characteristics of aerosolized antibiotics, reviews the advantages and disadvantages of using aerosolized antibiotics, and calls for future investigations based on animal study data.
BarbierF, AndremontA, WolffM, BouadmaL. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med, 2013; 19(3):216–228.
2.
ChastreJ, FagonJY. Ventilator-associated pneumonia. Am J Respir Crit Care Med, 2002; 165(7):867–903.
3.
WarrenDK, ShuklaSJ, OlsenMA, KollefMH, HollenbeakCS, CoxMJ, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med, 2003; 31(5):1312–1317.
4.
BergmansDC, BontenMJ, GaillardCA, van TielFH, van der GeestS, de LeeuwPW, StobberinghEE. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother, 1997; 39(4):527–535.
5.
FagonJY, ChastreJ, RoubyJJ. Is bronchoalveolar lavage with quantitative cultures a useful tool for diagnosing ventilator-associated pneumonia?. Crit Care, 2007; 11(2):123.
6.
ValckeY, PauwelsR, Van der StraetenM. Pharmacokinetics of antibiotics in the lungs. Eur Respir J, 1990; 3(6):715–722.
7.
RottbøllLA, FriisC. Penetration of antimicrobials to pulmonary epithelial lining fluid and muscle and impact of drug physicochemical properties determined by microdialysis. J Pharmacol Toxicol Methods, 2015; 78:58–65.
8.
KiemS, SchentagJJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother, 2008; 52(1):24–36.
9.
RatjenF, RietschelE, KaselD, SchwiertzR, StarkeK, BeierH, et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother, 2006; 57(2):306–311.
10.
NeuhauserMM, WeinsteinRA, RydmanR, DanzigerLH, KaramG, QuinnJP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA, 2003; 289(7):885–888.
11.
American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 2005; 171(4):388–416.
12.
SpierR, WitebskyE, PaineJR. Aerosolized pancreatic dornase and antibiotics in pulmonary infections: use in patients with postoperative and nonoperative infections. Jama, 1961; 178:878–886.
13.
LabirisNR, NewhouseMT. Drug delivery: pulmonary delivery. In Encyclopedia of Pharmaceutical Science and Technology, 4th Edition. Abingdon, UK: Taylor & Francis; 2013.
FlumeP, KlepserME. The rationale for aerosolized antibiotics. Pharmacotherapy, 2002; 22(3 Pt 2):71S–79S.
16.
ChalmersJD, SmithMP, McHughBJ, DohertyC, GovanJR, HillAT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med, 2012; 186(7):657–665.
17.
BrainJD, ValbergPA. Deposition of aerosol in the respiratory tract. Am Rev Respir Dis, 1979; 120(6):1325–1373.
18.
DolovichMA. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care, 2000; 45(6):597–608.
19.
StewartSM, AndersonIM, JonesGR, CalderMA. Amoxycillin levels in sputum, serum, and saliva. Thorax, 1974; 29(1):110–114.
20.
IngoldA. Sputum and serum levels of amoxycillin in chronic bronchial infections. Br J Dis Chest, 1975; 69:211–216.
21.
MaesenFP, BeeuwkesH, DaviesBI, BuytendijkHJ, BrombacherPJ, WessmanJ. Bacampicillin in acute exacerbations of chronic bronchitis: a dose-range study. J Antimicrob Chemother, 1976; 2(3):279–285.
SegalMS, LevinsonL, MillerD. Penicillin inhalation therapy in respiratory infections. J Am Med Assoc, 1947; 134(9):762–770.
24.
MakhoulIR, MerzbachD, LichtigC, BerantM. Antibiotic treatment of experimental Pseudomonas aeruginosa pneumonia in guinea pigs: comparison of aerosol and systemic administration. J Infect Dis, 1993; 168(5):1296–1299.
25.
GoldsteinI, WalletF, RobertJ, BecqueminMH, MarquetteCH, RoubyJJ. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med, 2002; 165(2):171–175.
26.
ElmanM, GoldsteinI, MarquetteCH, WalletF, LenaourG, RoubyJJ, Experimental ICU Study Group. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology, 2002; 97(1):199–206.
27.
TonnellierM, FerrariF, GoldsteinI, SartoriusA, MarquetteCH, RoubyJJ. Intravenous versus nebulized ceftazidime in ventilated piglets with and without experimental bronchopneumonia: comparative effects of helium and nitrogen. Anesthesiology, 2005; 102(5):995–1000.
28.
FerrariF, LuQ, GirardiC, PetitjeanO, MarquetteCH, WalletF, et al. Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa. Intensive Care Med, 2009; 35(10):1792–1800.
29.
LuQ, GirardiC, ZhangM, BouhemadB, LouchahiK, PetitjeanO, et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med, 2010; 36(7):1147–1155.
30.
BhavsarT, LiuM, LiuX, CantorJ. Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia. Exp Lung Res, 2011; 37(9):536–541.
31.
Le ConteP, PotelG, ClémentiE, LegrasA, VillersD, BironneauE, et al. [Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study]. Presse Med, 2000; 29(2):76–78.
32.
HallalA, CohnSM, NamiasN, HabibF, BaraccoG, ManningRJ, et al. Aerosolized tobramycin in the treatment of ventilator-associated pneumonia: a pilot study. Surg Infect, 2007; 8(1):73–82.
33.
GhannamDE, RodriguezGH, RaadII, SafdarA. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur J Clin Microbiol Infect Dis, 2009; 28(3):253–259.
34.
KofteridisDP, AlexopoulouC, ValachisA, MarakiS, DimopoulouD, GeorgopoulosD, SamonisG. Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis, 2010; 51(11):1238–1244.
35.
KorbilaIP, MichalopoulosA, RafailidisPI, NikitaD, SamonisG, FalagasME. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect, 2010; 16(8):1230–1236.
36.
RattanaumpawanP, LorsutthithamJ, UngprasertP, AngkasekwinaiN, ThamlikitkulV. Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother, 2010; 65(12):2645–2649.
37.
LuQ, YangJ, LiuZ, GutierrezC, AymardG, RoubyJJ. Nebulized Antibiotics Study Group. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med, 2011; 184(1):106–115.
38.
NiedermanMS, ChastreJ, CorkeryK, FinkJB, LuytCE, GarcíaMS. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med, 2012; 38(2):263–271.
39.
DoshiNM, CookCH, MountKL, StawickiSP, FrazeeEN, PersonettHA, et al. Adjunctive aerosolized colistin for multi-drug resistant gram-negative pneumonia in the critically ill: a retrospective study. BMC Anesthesiol, 2013; 13(1):45.
40.
TumbarelloM, De PascaleG, TrecarichiEM, De MartinoS, BelloG, MavigliaR, et al. Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria. Chest, 2013; 144(6):1768–1775.
41.
PalmerLB, SmaldoneGC. Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. Am J Respir Crit Care Med, 2014; 189(10):1225–1233.
42.
RoseLM, NealeR. Development of the first inhaled antibiotic for the treatment of cystic fibrosis. Sci Transl Med, 2010; 2(63):63mr64. doi: 10.1126/scitranslmed.3001634.
43.
KleinstreuerC, ZhangZ, LiZ. Modeling airflow and particle transport/deposition in pulmonary airways. Respir Physiol Neurobiol, 2008; 163(1):128–138.
44.
ByronPR. Prediction of drug residence times in regions of the human respiratory tract following aerosol inhalation. J Pharm Sci, 1986; 75(5):433–438.
45.
BoeJ, DennisJH, O'DriscollBR, BauerTT, CaroneM, DautzenbergB, et al. European Respiratory Society Guidelines on the use of nebulizers: guidelines prepared by a European Respiratory Society Task Force on the use of nebulizers. Eur Respir J, 2001; 18(1):228–242.
46.
FinkJ, AriA. Aerosol delivery to intubated patients: expert opinion on drug delivery. 2013; 10(8):1077–1093.
47.
HessDR, DillmanC, KacmarekRM. In vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control vs. volume control ventilation. Intensive Care Med, 2003; 29(7):1145–1150.
48.
PalmerLB, SmaldoneGC, ChenJJ, BaramD, DuanT, MonteforteM, et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med, 2008; 36(7):2008–2013.
49.
NseirS. Aerosolized antibiotics for ventilator-associated tracheobronchitis: let's go with the flow!. Crit Care Med, 2008; 36(7):2191–2192.
50.
MyersTR. Year in review 2014: aerosol delivery devices. Respir Care, 2015; 60(8):1190–1196.
51.
FullerHD, DolovichMB, PosmituckG, PackWW, NewhouseMT. Pressurized aerosol versus jet aerosol delivery to mechanically ventilated patients: comparison of dose to the lungs. Am Rev Respir Dis, 1990; 141(2):440–444.
52.
DubusJC, VecellioL, De MonteM, FinkJB, GrimbertD, MontharuJ, et al. Aerosol deposition in neonatal ventilation. Pediatr Res, 2005; 58(1):10–14.
53.
SteckelH, EskandarF. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci, 2003; 19(5):443–455.
54.
SagallaRB, SmaldoneGC. Capturing the efficiency of vibrating mesh nebulizers: minimizing upper airway deposition. J Aerosol Med Pulm Drug Deliv, 2014; 27(5):341–348.
55.
RoubyJJ, BouhemadB, MonselA, BrissonH, ArbelotC, LuQ, Nebulized Antibiotics Study Group. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. Anesthesiology, 2012; 117(6):1364–1380.
56.
SartoriusA, LuQ, VieiraS, TonnellierM, LenaourG, GoldsteinI, RoubyJJ. Mechanical ventilation and lung infection in the genesis of air-space enlargement. Crit Care, 2007; 11(1):R14.
57.
GoldsteinI, BughaloMT, MarquetteCH, LenaourG, LuQ, RoubyJJ, Experimental ICU Study Group. Mechanical ventilation-induced air-space enlargement during experimental pneumonia in piglets. Am J Respir Crit Care Med, 2001; 163(4):958–964.
58.
PelkonenAS, NikanderK, TurpeinenM. Jet nebulization of budesonide suspension into a neonatal ventilator circuit: synchronized versus continuous nebulizer flow. Pediatr Pulmonol, 1997; 24(4):282–286.
59.
MillerDD, AminMM, PalmerLB, ShahAR, SmaldoneGC. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am J Respir Crit Care Med, 2003; 168(10):1205–1209.
60.
O'RiordanTG, PalmerLB, SmaldoneGC. Aerosol deposition in mechanically ventilated patients: optimizing nebulizer delivery. Am J Respir Crit Care Med, 1994; 149(1):214–219.
61.
GoldsteinI, WalletF, Nicolas-RobinA, FerrariF, MarquetteCH, RoubyJJ. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med, 2002; 166(10):1375–1381.
62.
ValachisA, SamonisG, KofteridisDP. The role of aerosolized colistin in the treatment of ventilator-associated pneumonia: a systematic review and metaanalysis. Crit Care Med, 2015; 43(3):527–533.
63.
RamseyBW, PepeMS, QuanJM, OttoKL, MontgomeryAB, Williams-WarrenJ, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis: Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med, 1999; 340(1):23–30.
64.
McCoyKS, QuittnerAL, OermannCM, GibsonRL, Retsch-BogartGZ, MontgomeryAB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med, 2008; 178(9):921–928.
65.
ImbertiR, CusatoM, VillaniP, CarnevaleL, IottiGA, LangerM, RegazziM. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest, 2010; 138(6):1333–1339.
66.
HarveyCJ, O'DohertyMJ, PageCJ, ThomasSH, NunanTO, TreacherDF. Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Eur Respir J, 1997; 10(4):905–909.
67.
KlompasM. Interobserver variability in ventilator-associated pneumonia surveillance. Am J Infect Control, 2010; 38(3):237–239.
68.
KlompasM. Does this patient have ventilator-associated pneumonia?. JAMA, 2007; 297(14):1583–1593.
69.
KlompasM. The paradox of ventilator-associated pneumonia prevention measures. Crit Care, 2009; 13(5):315.
70.
TejerinaE, EstebanA, Fernández-SegovianoP, Frutos-VivarF, AramburuJ, BallesterosD, Rodríguez-BarberoJM. Accuracy of clinical definitions of ventilator-associated pneumonia: comparison with autopsy findings. J Crit Care, 2010; 25(1):62–68.
71.
ZampieriFG, NassarAPJr., Gusmao-FloresD, TaniguchiLU, TorresA, RanzaniOT. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Crit Care, 2015; 19:150.
72.
RoubyJJ, BouhemadB, MonselA, BrissonH, ArbelotC, LuQ; Nebulized Antibiotics Study Group. Aerosolized antibiotics for ventilator-associated pneumonia: lessons from experimental studies. Anesthesiology, 2012; 117(6):1364–1380.
73.
PanigadaM, BerraL, GrecoG, StylianouM, KolobowT. Bacterial colonization of the respiratory tract following tracheal intubation-effect of gravity: an experimental study. Crit Care Med, 2003; 31(3):729–737.
74.
LuQ, YangJ, LiuZ, GutierrezC, AymardG, RoubyJJ. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med, 2011; 184(1):106–115.
75.
PalmerLB, SmaldoneGC, ChenJJ, BaramD, DuanT, MonteforteM, et al. http://www.ncbi.nlm.nih.gov/pubmed/18552684 Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med, 2008; 36(7):2008–13.
